Adult acute respiratory distress syndrome
diseaseOn this page
Also known as adult ARDSadult respiratory distress syndromeadult respiratory distress syndrome, ARDSARDSrespiratory distress syndrome, adult
Summary
Adult acute respiratory distress syndrome (MONDO:0100130) is a disease and 462 clinical trials. Top therapeutic interventions include cisatracurium, sodium chloride, and meropenem. A subtype of acute respiratory distress syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-5 / 10 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 17
- Clinical trials: 462
Clinical features
Epidemiology
Prevalence records
8 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-5 / 10 000 | Europe | Validated | |
| Annual incidence | 6-9 / 10 000 | 64 | United States | Validated |
| Annual incidence | 1-9 / 100 000 | 7.2 | Spain | Validated |
| Annual incidence | 1-9 / 100 000 | 4.9 | Finland | Validated |
| Annual incidence | 1-5 / 10 000 | 13.5 | Sweden | Validated |
| Annual incidence | 1-5 / 10 000 | 13.5 | Denmark | Validated |
| Annual incidence | 1-5 / 10 000 | 11.5 | Iceland | Not yet validated |
| Point prevalence | 1-5 / 10 000 | 51 | United States | Not yet validated |
Signs & symptoms
Clinical features (HPO)
17 HPO clinical features (Orphanet curated; top 17 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0011117 | Abnormal circulating interleukin concentration | Very frequent (80-99%) |
| HP:0002094 | Dyspnea | Very frequent (80-99%) |
| HP:0002113 | Pulmonary infiltrates | Very frequent (80-99%) |
| HP:0012415 | Abnormal blood gas level | Very frequent (80-99%) |
| HP:0012418 | Hypoxemia | Very frequent (80-99%) |
| HP:0001942 | Metabolic acidosis | Frequent (30-79%) |
| HP:0002615 | Hypotension | Frequent (30-79%) |
| HP:0002878 | Respiratory failure | Frequent (30-79%) |
| HP:0011118 | Abnormality of tumor necrosis factor secretion | Frequent (30-79%) |
| HP:0030783 | Increased circulating interleukin 6 concentration | Frequent (30-79%) |
| HP:0031273 | Shock | Frequent (30-79%) |
| HP:0100598 | Pulmonary edema | Frequent (30-79%) |
| HP:0100806 | Sepsis | Frequent (30-79%) |
| HP:0002090 | Pneumonia | Occasional (5-29%) |
| HP:0001733 | Pancreatitis | Very rare (<1-4%) |
| HP:0001953 | Diabetic ketoacidosis | Very rare (<1-4%) |
| HP:0002633 | Vasculitis | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult acute respiratory distress syndrome |
| Mondo ID | MONDO:0100130 |
| MeSH | D012128 |
| Orphanet | 70578 |
| DOID | DOID:11394 |
| ICD-11 | 1466842111 |
| SNOMED CT | 67782005 |
| UMLS | C0035222 |
| MedGen | 20540 |
| GARD | 0018902 |
| Is cancer (heuristic) | no |
Also known as: adult acute respiratory distress syndrome · adult ARDS · adult respiratory distress syndrome · adult respiratory distress syndrome, ARDS · ARDS · respiratory distress syndrome, adult
Disease family
This is a subtype of acute respiratory distress syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › acute disease › acute respiratory failure › acute respiratory distress syndrome › adult acute respiratory distress syndrome
Related subtypes (1): pediatric acute respiratory distress syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Calfactant | Approved (phase 4) |
| Dexamethasone | Phase 3 (in late-stage trials) |
| Dornase Alfa | Phase 3 (in late-stage trials) |
| Hydroxychloroquine | Phase 3 (in late-stage trials) |
| INTERFERON BETA-1A | Phase 3 (in late-stage trials) |
| Iloprost | Phase 3 (in late-stage trials) |
| Ketoconazole | Phase 3 (in late-stage trials) |
| Methylprednisolone | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Alprostadil, Carbon Monoxide, Drotrecogin Alfa (Activated), Plasmalyte A, Reparixin, Roflumilast, Sabizabulin, Sodium Chloride, Treprostinil.
Clinical trials & evidence
Clinical trials
Clinical trials: 462.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 339 |
| PHASE2 | 55 |
| PHASE3 | 24 |
| PHASE1/PHASE2 | 15 |
| PHASE1 | 13 |
| PHASE4 | 7 |
| PHASE2/PHASE3 | 6 |
| EARLY_PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06934811 | PHASE4 | NOT_YET_RECRUITING | Ciprofol’s Impact on Oxygenator Function in Extracorporeal Membrane Oxygenation (ECMO) Patients |
| NCT00299650 | PHASE4 | COMPLETED | Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients |
| NCT01825304 | PHASE4 | UNKNOWN | The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation |
| NCT02902055 | PHASE4 | TERMINATED | Paediatric Ards Neuromuscular Blockade Study |
| NCT03337373 | PHASE4 | COMPLETED | The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium |
| NCT04014218 | PHASE4 | UNKNOWN | Effect of Inhalation Sedation Compared With Propofol on the Sepsis-related Acute Respiratory Distress Syndrome Course |
| NCT04663555 | PHASE4 | COMPLETED | Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19 |
| NCT03368092 | PHASE3 | RECRUITING | Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma |
| NCT05354141 | PHASE3 | RECRUITING | Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) |
| NCT05497401 | PHASE3 | NOT_YET_RECRUITING | A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS |
| NCT06526533 | PHASE3 | RECRUITING | RECOMMEND Platform Trial |
| NCT07588217 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury in Patients With ARDS - Pilot RCT |
| NCT00000579 | PHASE3 | COMPLETED | Acute Respiratory Distress Syndrome Clinical Network (ARDSNet) |
| NCT00308022 | PHASE2/PHASE3 | WITHDRAWN | Comparison Study of High Frequency Percussive Ventilation With Conventional Ventilation |
| NCT00434993 | PHASE2/PHASE3 | TERMINATED | Drug Study of Albuterol to Treat Acute Lung Injury |
| NCT00465309 | PHASE3 | COMPLETED | Protective Ventilation With Carbon Dioxide (CO2) -Removal Technique in Patients With Adult Respiratory Distress Syndrome (ARDS) |
| NCT00465374 | PHASE3 | UNKNOWN | A Validation/Interventional Study on Stress Index in Predicting Mechanical Stress in ARDS Patients |
| NCT00609180 | PHASE3 | TERMINATED | Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study) |
| NCT00682500 | PHASE3 | TERMINATED | Calfactant for Direct Acute Respiratory Distress Syndrome |
| NCT00883948 | PHASE3 | COMPLETED | Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study) |
| NCT01461889 | PHASE3 | TERMINATED | INR-Triggered Transfusion In GI Bleeders From ER |
| NCT02622724 | PHASE3 | TERMINATED | Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS) |
| NCT03111212 | PHASE3 | COMPLETED | Iloprost in Acute Respiratory Distress Syndrome |
| NCT03371498 | PHASE3 | TERMINATED | Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome |
| NCT04012073 | PHASE3 | TERMINATED | Individualized Positive End-expiratory Pressure Guided by End-expiratory Lung Volume in the Acute Respiratory Distress Syndrome |
| NCT04328467 | PHASE3 | COMPLETED | Pre-exposure Prophylaxis for SARS-Coronavirus-2 |
| NCT04347980 | PHASE3 | TERMINATED | Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19 |
| NCT04360096 | PHASE2/PHASE3 | TERMINATED | Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 |
| NCT04367077 | PHASE2/PHASE3 | UNKNOWN | MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) |
| NCT04395105 | PHASE3 | TERMINATED | Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial |
| NCT04401475 | PHASE2/PHASE3 | SUSPENDED | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 |
| NCT04402970 | PHASE3 | COMPLETED | Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) |
| NCT04499313 | PHASE3 | UNKNOWN | Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19 |
| NCT04530188 | PHASE3 | UNKNOWN | Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS |
| NCT04973670 | PHASE3 | UNKNOWN | Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis |
| NCT05137795 | PHASE3 | WITHDRAWN | Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 |
| NCT05453214 | PHASE3 | COMPLETED | Mineralocorticoid Use in COVID-19 Patients |
| NCT04365101 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 |
| NCT04545424 | PHASE2 | RECRUITING | Trial of Therapeutic Hypothermia in Patients With ARDS |
| NCT05515484 | PHASE2 | RECRUITING | Improvement of Lung and Thoracic Compliance in ARDS Patients in Prone Position by Using Inflatable Air Bag |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISATRACURIUM | 4 | 9 |
| SODIUM CHLORIDE | 4 | 6 |
| MEROPENEM | 4 | 3 |
| ALPROSTADIL | 4 | 2 |
| ALBUTEROL SULFATE | 4 | 1 |
| AXATILIMAB | 4 | 1 |
| CALFACTANT | 4 | 1 |
| DROTRECOGIN ALFA (ACTIVATED) | 4 | 1 |
| FLUDROCORTISONE ACETATE | 4 | 1 |
| HYDROXYCHLOROQUINE | 4 | 1 |
| ILOPROST | 4 | 1 |
| INTERFERON BETA-1A | 4 | 1 |
| KETOCONAZOLE | 4 | 1 |
| LEVOKETOCONAZOLE | 4 | 1 |
| ROFLUMILAST | 4 | 1 |
| TENECTEPLASE | 4 | 1 |
| SIVELESTAT | 3 | 6 |
| EMIPLACEL | 3 | 2 |
| AVIPTADIL | 3 | 1 |
| CIPEPOFOL | 3 | 1 |
| OMEGA-3 FATTY ACIDS | 3 | 1 |
| PLASMALYTE A | 3 | 1 |
| REGRAMOSTIM | 3 | 1 |
| SABIZABULIN | 3 | 1 |
| IC14 | 2 | 3 |
| RILDINADSTROCEL | 2 | 3 |
| BIO-11006 | 2 | 1 |
| FLUDROCORTISONE | 2 | 1 |
| GLENZOCIMAB | 2 | 1 |
| QUISOVALIMAB | 2 | 1 |
Related Atlas pages
- Drugs: Cisatracurium, Sodium Chloride, Meropenem, Alprostadil, Albuterol, Axatilimab, Calfactant, Drotrecogin Alfa (Activated), Fludrocortisone Acetate, Hydroxychloroquine, Iloprost, INTERFERON BETA-1A, Ketoconazole, Levoketoconazole, Roflumilast, Tenecteplase, Sivelestat, Emiplacel, Aviptadil, Cipepofol, OMEGA-3 FATTY ACIDS, Plasmalyte A, Regramostim, Sabizabulin